PHILADELPHIA, April 19 /PRNewswire/ -- InnaPhase Corporation, a world- leading provider of enterprise Laboratory Information Management System (LIMS) solutions, today announced that Apotex Inc., the largest Canadian-owned pharmaceutical company, has successfully and swiftly implemented and validated its Watson(TM) LIMS v. 7.0.
"The installation and implementation time must have set a new benchmark," said Dr. Jeremy Desai, Sr. Vice President, Research & Development, for Apotex. "The Apotex team with InnaPhase's support and guidance produced a seamless implementation of the software with virtually no adverse impact on lab productivity."
Watson(TM) is a built-for-purpose Laboratory Information Management System specifically designed to support DMPK/Bioanalytical studies in drug development. The system was developed by InnaPhase in conjunction with the world's major pharmaceutical companies to accelerate bioanalysis and sample management in drug development. Apotex has been using Watson LIMS in its bioanalytical laboratories since 2002 at the company's research facilities in Toronto, Ontario, Canada.
"InnaPhase is focused on meeting the business needs of our customers," said Jo Webber, PhD, President and Chief Executive Officer of InnaPhase. "The speed and efficiency of our implementations is critical to the productivity and success of our customers. The nature of our purpose-built solutions enables us to get end-users up and running in less time when compared to generic LIMS."
Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. Apotex employs over 6,000 people in research, development, manufacturing and distribution facilities worldwide. Apotex produces more than 230 generic pharmaceuticals in approximately 4,000 dosages and formats which, in Canada, are used to fill over 55 million prescriptions a year -- the largest amount of any pharmaceutical company in Canada.
InnaPhase Corporation provides 18 of the world's top 20 pharmaceutical organizations with its products and services. In addition to the EP Series, InnaPhase markets the 21 CFR Part 11 compliant Pharma LIMS(TM) Suite, a series of purpose-built LIMS applications which includes: Newton(TM) LIMS for batch release, quality control, formulation, stability and analytical development; Watson(TM) LIMS for pre-clinical and clinical bioanalysis; and Galileo(TM) LIMS for In Vitro testing. InnaPhase has locations in the United States, the United Kingdom, Germany, The Netherlands and distribution centers in India and Japan. For more information, see InnaPhase on the World Wide Web at http://www.innaphase.com/.
CO: InnaPhase Corporation; Apotex Inc.ST: PennsylvaniaIN: HEA BIO MTCSU: PDT